| Status | In progress |
| Process | STA 2018 |
| ID number | 3836 |
Provisional Schedule
| Committee meeting: 1 | 11 November 2021 |
| Expected publication | 02 February 2022 |
Project Team
| Project lead | Louise Jafferally |
Email enquiries
- If you have any queries please email TATeam4@nice.org.uk
Consultees
| Companies sponsors | Janssen-Cilag (amivantamab) |
| Others | Department of Health and Social care |
| NHS England | |
| NHS Herefordshire and Worcestershire CCG | |
| NHS Hillingdon CCG | |
| Welsh Government | |
| Patient carer groups | Black Health Agency for Equality |
| British Lung Foundation | |
| Cancer Black Care | |
| Cancer Equality | |
| EGFR Positive UK | |
| Helen Rollason Cancer Charity | |
| Independent Cancer Patients Voice | |
| Macmillan Cancer Support | |
| Maggie’s Centres | |
| Marie Curie | |
| Roy Castle Lung Cancer Foundation | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Tenovus Cancer Care | |
| UK Lung Cancer Coalition | |
| Professional groups | Association of Cancer Physicians |
| Association of Respiratory Nurse Specialists | |
| British Geriatrics Society | |
| British Institute of Radiology | |
| British Psychosocial Oncology Society | |
| British Society of Interventional Radiology | |
| British Thoracic Oncology Group | |
| British Thoracic Society | |
| Cancer Research UK | |
| Lung Cancer Nursing UK | |
| National Heart and Lung Institute | |
| Primary Care Respiratory Society UK | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Society and College of Radiographers | |
| UK Clinical Pharmacy Association | |
| UK Oncology Nursing Society |
Commentators
| Associated guideline groups | National Guideline Alliance |
| Associated public health groups | Public Health England |
| Public Health Wales | |
| Comparator companies | Accord Healthcare (docetaxel, carboplatin) |
| Boehringer Ingelheim (nintedanib) | |
| Bristol-Myers Squibb (nivolumab) | |
| Consilient Health (carboplatin) | |
| Eli Lilly and Company (pemetrexed) | |
| Hospira UK (docetaxel, carboplatin) | |
| MSD (pembrolizumab) | |
| Roche products (atezolizumab) | |
| Seacross Pharmaceuticals (docetaxel, pemetrexed) | |
| General commentators | All Wales Therapeutic and Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| NHS Alliance | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Cochrane Lung Cancer Group |
| Genomics England | |
| Institute of Cancer Research | |
| MRC Clinical Trials Unit | |
| National Cancer Research Institute | |
| National Cancer Research Network | |
| National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 March 2021 | Invitation to participate |
| 13 January 2021 - 10 February 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 01 September 2020 | In progress. DHSC referral received |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance